In the context of TET2-mutation-positive CH, prophylactic treatment for atherosclerosis using cholesterol-lowering medications or compounds targeting IL-1β and other inflammatory pathways as proposed2,4,5 would, if effective, be a significant advance. This evidence concerns the gene IL1B and atherosclerosis.